Refractive Error and Biometry in Retinopathy of Prematurity
NCT03334513 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35
Last updated 2017-11-07
Summary
The investigators compared long-term refractive and biometric outcomes in children with retinopathy of prematurity who received two different anti-vascular endothelial growth factor agents.
Conditions
- Retinopathy of Prematurity
Interventions
- DRUG
-
intravitreal injection of bevacizumab
- DRUG
-
intravitreal injection of ranibizumab
Sponsors & Collaborators
-
San Ni Chen
lead OTHER
Eligibility
- Min Age
- 3 Years
- Max Age
- 3 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-04-01
- Primary Completion
- 2014-04-01
- Completion
- 2014-04-01
- FDA Drug
- Yes
More Related Trials
-
Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis
NCT00804934 ·Status: COMPLETED
-
SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
NCT03409250 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
NCT00470977 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab
NCT00559715 ·Status: UNKNOWN ·Phase: PHASE3
-
Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.
NCT01972763 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease
NCT00841373 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)
NCT04922151 ·Status: UNKNOWN ·Phase: PHASE2
-
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT03834753 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
NCT01217944 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF
NCT03071055 ·Status: COMPLETED ·Phase: PHASE2
-
Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization
NCT03042871 ·Status: COMPLETED ·Phase: PHASE4
-
Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
NCT00395707 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
NCT01469156 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity
NCT05701124 ·Status: COMPLETED ·Phase: PHASE3
-
RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity
NCT02375971 ·Status: COMPLETED ·Phase: PHASE3
-
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
NCT00749021 ·Status: COMPLETED ·Phase: PHASE1
-
Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
NCT00681889 ·Status: COMPLETED ·Phase: PHASE1
-
CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography
NCT00500344 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
NCT01922102 ·Status: COMPLETED ·Phase: PHASE3
-
Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab
NCT02309281 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
NCT06460844 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy
NCT01360151 ·Status: UNKNOWN ·Phase: NA
-
Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD
NCT01269151 ·Status: COMPLETED ·Phase: NA
-
Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
NCT01535261 ·Status: COMPLETED ·Phase: PHASE3
-
Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD
NCT03393767 ·Status: COMPLETED ·Phase: PHASE4